Selected Grants
A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2022 - 2027A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2021 - 2026A Window-of-Opportunity Trial Using Neoadjuvant Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
ResearchCollaborator · Awarded by Marc Lustgarten Pancreatic Cancer Foundation · 2023 - 2026Pfizer - C4201002 - PF-07265807
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2020 - 2025Adapting K-MDS to detect KRAS-mutant ctDNA
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2022 - 2025A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2022 - 2027A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2021 - 2026A Window-of-Opportunity Trial Using Neoadjuvant Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
ResearchCollaborator · Awarded by Marc Lustgarten Pancreatic Cancer Foundation · 2023 - 2026Pfizer - C4201002 - PF-07265807
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2020 - 2025Adapting K-MDS to detect KRAS-mutant ctDNA
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2022 - 2025Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2023Cancer Therapy Evaluation Program Administrative Agreement
Clinical TrialPrincipal Investigator · Awarded by Leidos Biomedical Research, Inc. · 2022 - 20223D Biology Signatures defined by Nanostring Max System
EquipmentMajor User · Awarded by North Carolina Biotechnology Center · 2018 - 2019Preclinical and Human Correlative Studies of a Novel Bruton Tyronsine Kinase Inhibitor in Pancreatic Cancer
ResearchCo Investigator · Awarded by Department of Defense · 2016 - 2017Topic Refinement, Task order 9 Topic Briefs
ResearchCo Investigator · Awarded by Patient-Centered Outcomes Research Institute · 2016 - 2016External Relationships
- American Association for Cancer Research
- Amgen, Inc.
- Bessor Pharma
- Lustgarten Foundation
- Moleculin Biotech Inc.
- American Association for Cancer Research
- Amgen, Inc.
- Bessor Pharma
- Lustgarten Foundation
- Moleculin Biotech Inc.
- Pancreatic Cancer Action Network
- Pancreatic Cancer United Kingdom
- Pfizer Inc.
- University of Nebraska Medical Center
- Vanderbilt University
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.